TrialKidney international2014

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.

Donald E Kohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.